Latest Hotspot

Intravacc reveals encouraging initial human trial results for its novel OMV nasal spray vaccine against COVID-19

29 March 2024
3 min read

Intravacc, a globally recognized pioneer in the field of translational research as well as the creation of vaccines for both prevention and treatment, has shared encouraging results from initial human trials of Avacc 10. This vaccine is designed as an intranasal booster, utilizing outer membrane vesicles, targeting the novel coronavirus, SARS-CoV-2. The foundational goals of this first-in-human trial included establishing the safe use, acceptable tolerance levels, and the ability to provoke an immune response when Avacc 10 is delivered through the nasal passage.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

A clinical investigation's initial phase, executed in the Australian setting, concentrated on determining the acceptability, security, and immune response eliciting capacity of the Avacc 10 inoculation. The experiment employed a structured process characterized by random assignment, double-blind secrecy, and a control involving placebos as well as Outer Membrane Vesicles. It involved the participation of 36 robust individuals - an assembly of men and women between 18 to 55 years. Each participant was administered a duo of nasal sprays containing the Avacc 10 formulation, separated by a three-week interval. Subdividing the participants, one cohort received a lesser quantity while another was given a greater quantity of the Avacc 10 dosage.

During the ensuing half-year after the administration of the vaccine, both cohorts were under observation. The investigative effort further included gauging Avacc 10's effectiveness in prompting an immunological reaction by examining specific immune elements like IgA and IgG, as well as antibodies with virus-neutralizing capabilities, particularly in those volunteers who already had considerable amounts of IgG antibodies directed against the SARS-CoV-2 virus.

The administration of the Avacc 10 inoculation proceeded without any noted incidents of negative reactions that might have necessitated the cessation of a participant's involvement in the study. Notably, the immunological engagement findings for the cohort which had received the amplified dosage of Avacc 10 showcased an initiation of an immune response within the mucous membranes.

Intravacc's Lead Scientist for Research & Development, Dr. Dinja Oosterhoff, commented: “The positive outcomes reflecting the immune activation from our Phase 1 assessment of Avacc 10® decidedly affirm the potential of an OMV-bolstered vaccine in enhancing the body's immune defenses.”

Moreover, Intravacc’s principal executive, Dr. Jan Groen, elaborated: “The initialization of this first-in-human (FIH) intranasal vaccine trial is a crucial advancement for Intravacc's primary OMV-dependent vaccine technology. As part of expanding our technology's purview, Intravacc is embarked on formulating an intranasal solution targeting Gonorrhea set for its first human trials in the last quarter of 2025. Concurrently, Intravacc has successfully entered into licensing agreements for its OMV-dependent vaccines with major pharmaceutical entities.”

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of March 27 2024, there are 454 investigational drugs for the SARS-CoV-2 S protein target, including 43 indications, 430 R&D institutions involved, with related clinical trials reaching 1040, and as many as 974 patents.

AVACC-10 is a vaccine developed by the Institute for Translational Vaccinology that specifically targets the SARS-CoV-2 S protein. It is intended to be used for the prevention and treatment of COVID-19, particularly in the context of infectious and respiratory diseases. Currently, AVACC-10 is in Phase 1 of its development, indicating that it has undergone initial testing in humans to assess its safety and dosage.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

What is Bioequivalence?
"What" Series
2 min read
What is Bioequivalence?
29 March 2024
Bioequivalence is a pharmacological term used to describe the similarity in the pharmacokinetic profiles of two drug products, usually a brand-name drug and a generic drug.
Read →
AST-201: Aptamer Sciences' Novel Therapy for Liver Cancer in NDA Submission
Latest Hotspot
4 min read
AST-201: Aptamer Sciences' Novel Therapy for Liver Cancer in NDA Submission
29 March 2024
Aptamer Sciences Submits New Drug Application for Groundbreaking Hepatocellular Carcinoma Therapy AST-201: A Potential Solution for Unmet Treatment Requirements.
Read →
Strategically Search Nortriptyline on Synapse: A How-to Guide
Drug Insights
2 min read
Strategically Search Nortriptyline on Synapse: A How-to Guide
29 March 2024
Nortriptyline, a monoamine reuptake inhibitor, is a small molecule drug that exhibits its pharmacological action by targeting MATs.
Read →
Novo Nordisk plans to purchase Cardior Pharmaceuticals, bolstering its portfolio in heart health management
Latest Hotspot
3 min read
Novo Nordisk plans to purchase Cardior Pharmaceuticals, bolstering its portfolio in heart health management
29 March 2024
Novo Nordisk has entered into an acquisition agreement with Cardior Pharmaceuticals, with the deal amounting to a maximum of 1.025 billion Euros.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.